A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03800134. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
Study identification
- NCT ID
- NCT03800134
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 825 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Placebo Other
- Carboplatin Drug
- Cisplatin Drug
- Pemetrexed Drug
- Paclitaxel Drug
- Gemcitabine Drug
- Surgery Procedure
Drug · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2018
- Primary completion
- Nov 9, 2022
- Completion
- Sep 10, 2028
- Last update posted
- Jun 10, 2025
2018 – 2028
United States locations
- U.S. sites
- 31
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Aurora | Colorado | 80012 | — |
| Research Site | Boca Raton | Florida | 33486 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Wichita | Kansas | 67214 | — |
| Research Site | Ashland | Kentucky | 41101 | — |
| Research Site | Lexington | Kentucky | 40513 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Duluth | Minnesota | 55805 | — |
| Research Site | Minneapolis | Minnesota | 55404 | — |
| Research Site | Morristown | New Jersey | 07962 | — |
| Research Site | New York | New York | 10028 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Shirley | New York | 11967 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Bend | Oregon | 97701 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Charleston | South Carolina | 29414 | — |
| Research Site | Charleston | South Carolina | 29424 | — |
| Research Site | Austin | Texas | 78745 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Kirkland | Washington | 98034 | — |
| Research Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 200 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03800134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03800134 live on ClinicalTrials.gov.